Government News

Drugs may withdrawn from Indian market if they banned in other countries

  • Posted on: 5 June 2015
  • By: PharmaTutor News

Drugs Controller General India (DCGI) has issued a notice in observance of the compliance for patient safety which seems more appealing and beneficial. DCGI notified to drug importers that they will inform or report to Indian authorities about time to time regulatory actions taken on their drugs in different countries where drugs are sold or distributed.

ICMR to begin research to identify and understand the local causes and risk factors on stillbirth

  • Posted on: 2 June 2015
  • By: Shalini.Sharma

The Indian Council of Medical Research (ICMR) will soon start research on stillbirth to identify and understand the local causes and risk factors from the medical and sociological perspective. ICMR's initiative on stillbirth is significant as nearly 3 million third-trimester stillbirths occurring worldwide each year and 98 per cent of these occur in low-income and middle-income countries.  More than 1 million stillbirths occur in the intrapartum period, which can largely be prevented. The cause of stillbirth remains unidentified in India.

Global Action Plan on Anti-Microbial Resistance adopted by India

  • Posted on: 28 May 2015
  • By: PharmaTutor News

The Minister of Health & Family Welfare Shri Jagat Prakash Nadda successfully steered the proceedings of the 68th Session of the World Health Assembly in his capacity as its President. It was after a gap of 19 years that India assumed the Presidency of the World Health Assembly, the highest decision making body of the World Health Organisation. The 68th WHA took place in Geneva from 18-26 May 2015.

Govt to Tie-up with institutes to advance homoeopathy research

  • Posted on: 23 May 2015
  • By: PharmaTutor News

An autonomous body under the AYUSH department of Union Health Ministry is planning to tieup with top homeopathy research organisations with an aim of boosting the healthcare industry. The Central Council for Research in Homeopathy (CCRH), the autonomous body under AYUSH, has called for further research to promote this system of medicine, said Dr R K Manchanda, Director General of CCRH.

It's Time to See - exclusive preview of exhibition shown to commonwealth health ministers, focusing on major cause of Avoidable Blindness - Retinopathy of Prematurity - in India

  • Posted on: 18 May 2015
  • By: PharmaTutor News

(Business Wire India); Today, at the 2015 Commonwealth Health Ministers’ Meeting in Geneva, The Queen Elizabeth Diamond Jubilee Trust and partner Standard Chartered have unveiled an exclusive preview of Time to See, a landmark photography exhibition which captures the human impact of avoidable blindness in the Commonwealth, and the solutions readily available.

  • Time to See – multi-award winning photographers join forces to bring to world’s attention major causes of avoidable blindness
  • 80% of world’s blindness is avoidable. Exhibition Time to See shows human impact and work being delivered by The Queen Elizabeth Diamond Jubilee Trust, Standard Chartered and partners to end avoidable blindness.

Indian doctors evolve new surgical technique to treat severe drug resistant epilepsy

  • Posted on: 18 May 2015
  • By: Shalini.Sharma

Doctors at the All India Institute of Medical Sciences (AIIMS), Delhi, have developed a novel technique of minimally invasive surgery to perform a complete unilateral hemispheric disconnection of the brain. This procedure is sometimes required for patients especially children who have severe drug resistant epilepsy.

India will share its part in first clinical study using stem cells to cure spinal cord injury

  • Posted on: 14 May 2015
  • By: Shalini.Sharma

India will bea part of a first-of-its-kind clinical trial for treating spinal cord injury in humans through stem-cells involving 18 patients. The clinical trial is a part of a collaborative study conducted in China, Norway and America involving 240 patients. The pre-clinical trial of this project already completed in the US and also the first phase clinical trials in China involving 120 patients.